Fluzoparib in Combination With Camrelizumab and Temozolomide in Advanced Melanoma

Sponsor
Jun Guo
Study ID
NCT05983237
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to evaluate how well fuzoparib in combination with camrelizumab and temozolomide works in treating patients with advanced, metastatic melanoma with the homologous recombination (HR) pathway gene mutation / alteration.

Key Dates

Start date
Aug 15, 2023
Status verified
Feb 2025
Primary completion
Dec 31, 2026
Completion
Dec 31, 2027

Study Design

Enrollment
50 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Camre+Fluzo+TMZ
    This arm will enroll patients who has advanced melanoma with a genetic HR mutation/ alteration .

Primary Outcome Measure

Objective Response Rate (ORR) [ Time Frame: 6 months ]

Central Contacts

Related Studies